临床决策支持工具引导的,在克罗恩病患者中选择性强度诱导乌斯特基努马布的策略:一个多中心队列研究
Qing Li1,2,3, Jian Tang1,2,3, Zhao Peng Huang1,2,3
1Department of Gastroenterology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong Province, China.
Journal of digestive diseases
|December 22, 2024
概括
由临床决策支持工具 (CDST) 指导的强化诱导疗法 (IIT) 对克罗恩病患者的预测反应不佳的乌斯特基努马布 (UST) 的预测显著改善了结果. 这种方法为患者分层和治疗优化提供了一个新的策略.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 临床药理学 临床药理学
背景情况:
- 克罗恩病 (CD) 管理需要有效的诱导策略.
- 乌斯特基努马布 (UST) 是一种生物治疗CD的疗法,但预测反应可能具有挑战性.
- 临床决策支持工具 (CDST) 可能有助于优化治疗选择.
研究的目的:
- 评估CDST指导的强化诱导疗法 (IIT) 对接受UST的CD患者的有效性和安全性.
- 确定最有可能从IIT中受益的患者子组.
- 为了比较IIT与标准治疗 (ST) 在活跃的CD.
主要方法:
- 在296名活跃CD患者的多中心回顾性研究中.
- 患者被分为使用UST-CDST的低概率,中等概率和高概率响应者.
- IIT涉及密集的初始UST剂量;ST作为对照. 主要终点:在第24周无皮质类固醇临床缓解 (CFCR).
主要成果:
- 与ST相比,IIT显著改善了CFCR (72.3%与43.0%相比),临床缓解 (77.3%与47.1%相比) 和内镜反应 (58.6%与36.9%相比) 在低中间响应者中 (p<0.001).
- 在高概率响应者中没有观察到终点的显著差异.
- 没有报告任何严重的不良事件.
结论:
- 在克罗恩氏病患者中,CDST指导的IIT显示出优于ST的疗效,预计对ustekinumab的反应不佳.
- 这种方法代表了基线患者分层的新策略.
- 在特定的患者亚组中,IIT可能会优化ustekinumab治疗.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
95
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
95
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
141
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
141
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
315
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
315
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
115
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
115
Inflammatory Bowel Disease V: Surgical Management
116
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
116
Inflammatory Bowel Disease IV: Pharmacological Management
111
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
111


